A&B achieves probiotic patent for treatment of chronic digestive diseases
22 Nov 2017 --- A&B Ingredients’ probiotic PA5051 has been issued a new patent as a method for treatment of chronic digestive diseases. The new patent covers both inflammatory bowel disorder (IBD) and nonspecific enteropathy (NEP), and can be used as a treatment for both humans and animals.
The company’s newly issued patent adds to PA5051’s portfolio of patents and expands the novel applications of PA5051 on reducing the side effects of prescription medicines such as steroids and immune suppressors.
“Currently, PA 5051 can be used as a nutrition supplement to support digestive systems and immune responses,” an A&B ingredients spokesperson explains to NutritionInsight of the product’s commercial applications. “PA 5051 can be used in dairy foods such as yogurt and cheese, and has been incorporated into snack foods such as chocolate, granola bars, whey protein and smoothie mixes to help body fat control, digestive systems and immune responses. In the future, PA5051 could be used together with prescription medicines to reduce the side effects caused by prescription medicines.”
PA5051 has recently achieved patents for: decreasing both the dosages and application times of steroid and immune suppressor agents for autoimmune diseases; inflammatory bowel disease; inflammatory-like bowel disease; immune-mediated hemolytic anemia; or atopic dermatitis.
“PA5051 is a unique natural, plant-based non-spore forming probiotic that is proven to aid in chronic digestive disorders among humans and animals,” comments Gil Bakal, A&B Ingredients’ Managing Director. “Derived from wild grasses, PA5051 works extremely well with antibiotics, steroids and immune suppressors functioning as an immune modulator to lower inflammation.”
Bakal also notes that because PA5051 is plant-based, it is also a vegan-friendly probiotic.
“PA5051 is a plant-based probiotic and isolated from the natural environment,” says the A&B Ingredients spokesperson. “Therefore, PA5051 has to be able to survive the harsh and constantly changing natural environment such as variable temperatures from cold, freezing, snowy winter days to hot summer days, exposure to acid rain, toxic chemicals from other microorganisms or secretions from animals.”
“Through the physiological, high-temperature selection of Pedioccocus acidilactici probiotics, PA5051 has been selected and found to be able to resist high temperatures up to 85 C and stomach acids,” adds the A&B Ingredients spokesperson. “It is more tolerant to antibiotics treatment, and can survive through yogurt pasteurization. When PA5051 is in freeze-dried powder form, it is stable at room temperature for two years.”
There are four pending patents for PA5051, the A&B Ingredients spokesperson notes. They are said to be related to: weight management; modulation of immune-related inflammation; applying dairy yogurt and/or plant-based yogurt as non-conventional probiotic delivery systems; and unique carriers for improving the survival rate of PA5051 through pasteurization.
The spokesperson reports that a PA5051 double-blind study on the relationships between inflammation and weight management has recently been completed. In addition, there is an ongoing gut microbiome study on the application of PA5051 with antibiotics treatment concurrently for acute diarrhea and chronic diarrhea. There is also a study being done into PA5051’s effects on improving radiation therapy on prostate cancer patients.
By Paul Creasy
